“Optimization of Aotus nancymaae non-human primate model for the development of multivalent Dengue vaccines using a self-amplifying RNA platform”.
ID: 1301227990Type: Solicitation
Overview

Buyer

DEPT OF DEFENSEDEPT OF THE NAVYNAVAL MEDICAL RESEARCH CENTERSILVER SPRING, MD, 20910-7500, USA

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES (AN14)

Original Source

https://sam.gov/opp/2e964d344fad4d43a5e42afc6d1810dc/view
Timeline
    Description

    The Department of Defense, through the Naval Medical Research Center, is seeking proposals for the optimization of the Aotus nancymaae non-human primate model to facilitate the development of multivalent Dengue vaccines utilizing a self-amplifying RNA platform. This procurement aims to enhance research and development efforts in the field of health, specifically targeting innovative vaccine solutions against Dengue fever. The project will be conducted in Peru, emphasizing the importance of advancing medical research in tropical diseases. Interested parties can reach out to Genaro Vasquez at genaro.m.vasquez.ln@health.mil or by phone at 0115116244128 for further details regarding the solicitation process.

    Point(s) of Contact
    Genaro Vasquez
    0115116244128
    genaro.m.vasquez.ln@health.mil
    Files
    No associated files provided.
    Similar Opportunities
    Scientific, Technical Research and Program Management Support Services for USAMRIID
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is seeking proposals for scientific and technical research and program management support services for the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). The procurement aims to enhance research capabilities in biotechnology, specifically focusing on health-related research and development services. This opportunity is critical for advancing the understanding and management of infectious diseases, thereby supporting national health security. Interested parties should note that this is an 8(a) set-aside contract, and inquiries can be directed to Christina Lewis at christina.m.lewis14.civ@health.mil or Jayme Fletcher at jayme.l.fletcher2.civ@health.mil.
    NIAID Virology Quality Assurance
    Buyer not available
    The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals for the Virology Quality Assurance (VQA) program under RFP number 75N93024R00030, aimed at enhancing quality assessment for virologic testing in clinical trials related to HIV and other viral pathogens. The program requires contractors to provide comprehensive quality assurance services, including performance validation reports and progress updates, while adhering to strict federal regulations and ethical standards concerning human subjects in research. This initiative is critical for establishing robust quality controls in virology testing, thereby supporting public health responses and ongoing research efforts. Proposals are due by April 8, 2025, at 3:00 PM EST, and interested parties should direct inquiries to Shawnice Williams at shawnice.williams@nih.gov or Ashley Kinderdine at ashley.kinderdine@nih.gov for further clarification.
    Monoclonal Antibodies and Viral Recombinant Antigens
    Buyer not available
    The Department of Defense, through the Defense Health Agency (DHA), is seeking suppliers for monoclonal antibodies and viral recombinant antigens, as outlined in a Special Notice. This procurement aims to acquire in vitro diagnostic substances, reagents, test kits, and sets, which are critical for various medical and research applications within the military health system. The place of performance for this contract will be in Maryland, United States, and interested vendors can reach out to Shelley Wallace at shelley.a.wallace2.civ@health.mil or Tonya Kreps at tonya.r.kreps.civ@health.mil for further information. The notice does not specify a funding amount or key deadlines, but interested parties are encouraged to inquire for additional details.
    In Vitro Assessments of Antimicrobial Activity
    Buyer not available
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking proposals for the In Vitro Assessments of Antimicrobial Activity (IVAAA) program through solicitation RFP 75N93024R00024. This initiative aims to support in vitro testing to evaluate the therapeutic potential of compounds against over 270 infectious agents, facilitating the development of vaccines, therapeutics, and diagnostics for infectious diseases. The program is critical for enhancing public health preparedness and response capabilities, particularly in addressing emerging health threats such as bioterrorism and infectious diseases. Proposals are due by March 10, 2025, with a funding range of $2,500 to $15 million available through January 14, 2033. Interested parties can direct inquiries to Alexander Beraud at alexander.beraud@nih.gov or Brian Madgey at brian.madgey@nih.gov.
    BROAD AGENCY ANNOUNCEMENT - BIOMEDICAL RESEARCH AND DIVING EQUIPMENT DEVELOPMENT
    Buyer not available
    The Department of Defense, specifically the Naval Sea Systems Command (NAVSEA), is soliciting proposals through a Broad Agency Announcement (BAA) for biomedical research and diving equipment development aimed at enhancing diver health, safety, and performance, as well as submarine escape and rescue capabilities. The primary objectives include improving diving equipment and biomedical aspects related to diver operations, with a focus on areas such as breathing gas supply, human performance, environmental protection, decompression, and submarine rescue strategies. This initiative is critical for advancing the safety and effectiveness of Navy personnel during underwater operations, with contracts typically averaging around $300,000 annually. Interested parties must submit pre-proposals by November 30, 2024, for FY26 funding, with full proposals due by February 28, 2025. For further inquiries, contact Lisa Grayum at lisa.m.grayum.civ@us.navy.mil or Daniel Kough at daniel.w.kough2.civ@us.navy.mil.
    CDI Laboratories HuProt v4.0 Human Proteome Microarrays (100) with Biospecimen Screening Service and Analysis
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking proposals for the procurement of 100 HuProt v4.0 Human Proteome Microarrays along with biospecimen screening services and analysis. This initiative aims to support the National Institute of Mental Health's efforts in autoantibody discovery and validation, utilizing advanced technologies to minimize the use of irreplaceable human biospecimens. The selected contractor will be responsible for screening 100 biospecimens for IgG and IgA antibodies and providing comprehensive analytical results, with the performance period set from March 17, 2025, to June 17, 2025. Interested parties should contact Marlene Milgram at marlene.milgram@nih.gov or call 13015940864 for further details regarding this total small business set-aside opportunity.
    Psychological Health and Research Support for the Naval Health Research Center
    Buyer not available
    The Department of Defense, through the Naval Health Research Center, is seeking proposals for psychological health and research support services. The objective of this procurement is to enhance research capabilities in the field of psychological health, which is critical for the well-being of military personnel and their families. The services will focus on applied research and development in health-related areas, contributing to the overall mission of improving mental health outcomes within the Navy. Interested parties can reach out to Helen Tyson at 215-697-9653 or via email at helen.tyson@navy.mil for further details regarding the solicitation process.
    Anti-human IgG Fc Capture Biosensors
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking qualified vendors to supply Anti-human IgG Fc Capture Biosensors for research at the Vaccine Research Center (VRC). This Sources Sought Notice, identified as SS-NIAID-25-2255392, aims to assess the capabilities of potential suppliers for biosensors that are compatible with the Octet HTX system, which are crucial for measuring protein interactions in vaccine development efforts against pathogens such as HIV-1 and SARS-CoV-2. Vendors are invited to submit a capability statement by March 12, 2025, detailing their qualifications, while adhering to Small Business Administration size standards and indicating interest in socio-economic business categories. Interested parties should direct their responses through the NIAID's electronic Simplified Acquisition Submission System (eSASS), noting that this notice does not obligate the government to award contracts and that all submissions will be reviewed at the government's discretion. For further inquiries, vendors may contact Leah Hinson at leah.hinson@nih.gov.
    ACME FNC
    Buyer not available
    The Department of Defense, through the Office of Naval Research, is soliciting proposals for the ACME FNC project, focusing on research and development in the physical, engineering, and life sciences. The objective of this procurement is to engage qualified entities capable of delivering innovative solutions that align with national defense research and experimental development needs. The services sought are critical for advancing military capabilities and ensuring technological superiority. Interested parties can reach out to Jeanne K. Garcia at jeanne.k.garcia.civ@us.navy.mil or call 703-696-0554 for further details regarding the solicitation process.
    Serological Assays for the Detection and Characterization of Influenza Viruses
    Buyer not available
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is soliciting proposals for a contract to provide serological assays for the detection and characterization of influenza viruses. The primary objectives include performing hemagglutination inhibition (HAI) assays on human serum samples and developing new serology assays, with an emphasis on high-throughput testing capabilities to enhance influenza surveillance and vaccine effectiveness studies. This procurement is critical for bolstering public health response capabilities during influenza threats, ensuring compliance with government regulations and performance metrics. Interested parties should contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020, with the Phase I interest submission deadline extended to February 21, 2025, and the contract's base period commencing on July 21, 2025.